Table 1

Patient characteristics

Web group
(n=91)
FENO group
(n=92)
Standard care group (n=89)p Value
Age (year)10.6 (2.8)10.3 (2.9)10.2 (3.2)0.57
Male60 (66)62 (67)61 (69)0.94
Height145.9 (17.0)144.3 (16.2)141.5 (16.6)0.20
Initial ICS dose, μg400 μg (400–800)400 μg (400–800)400 μg (400–800)0.97
LABA use42 (46)44 (48)40 (45)0.93
LTRA use11 (12)12 (13)11 (12)0.98
FENO, ppb17.1 (10.0–30.0)15.4 (10.0–26.3)21.4 (10.5–35.1)0.64
FEV1, %pred98.1 (12.6)95.2 (12.6)93.9 (14.0)0.11
FVC, %pred103.3 (12.2)100.3 (12.8)101.0 (13.0)0.29
FEF75, %pred91.0 (35.7)87.3 (33.1)76.0 (29.3)0.01
PD20, μg methacholine178.5 (26.3–738.7)118.1 (41.0–1084.4)158.2 (36.6–379.9)0.46
ACT or C-ACT score22.1 (3.5)20.7 (4.3)21.1 (3.3)0.03
ACT≥2073 (81)60 (65)62 (70)0.05
Daily symptom score1.1 (1.3)1.4 (1.7)1.3 (1.4)0.26
Daily SABA, puffs0.4 (0.8)0.6 (1.2)0.4 (0.8)0.29
Symptom-free days, %60 (33)53 (34)54 (35)0.26
PAQLQ score child6.3 (5.9–6.6)6.0 (5.6–6.6)6.2 (5.9–6.6)0.65
PACQLQ score parent6.7 (6.2–7.0)6.3 (5.7–6.8)6.1 (5.8–6.8)0.01
  • Data shown are numbers of patients (%), mean (SD) or median (IQR).

  • ACT, asthma control test; C-ACT, Childhood ACT; FEF75, forced expiratory flow at 25% of vital capacity; ICS, inhaled corticosteroids; LABA, long-acting β agonist; LTRA, leukotriene receptor antagonist; PACQLQ, Paediatric Asthma-Related Caregiver Quality of Life Questionnaire; PAQLQ, Paediatric Asthma-Related Quality of Life Questionnaire; PD20, doses of methacholine causing a 20% fall in FEV1; SABA, short-acting β agonist.